Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Biocryst Pharma Inc (BCRX)

4.9 -0.01 (-0.2%)

04-23 16:00

Open:

4.95

Pre. Close:

4.91

High:

4.9842

Low:

4.79

Volume:

325,105

Market Cap:

483M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

4.986 - 5.011

5.011 - 5.034

Low:

4.72 - 4.75

4.75 - 4.779

Close:

4.844 - 4.892

4.892 - 4.94

Technical analysis  (as of: 2018-04-23 4:27:23 PM)

Overall:

      

Stoxline posted a SELL today, same as yesterday. This stock seems to continue bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.

Target:

Six months: 5.93     One year: 6.32

Support:

Support1: 4.53    Support2: 3.77

Resistance:

Resistance1: 5.07    Resistance2: 5.41

Pivot:

4.92

Moving Averages:

MA(5): 4.99     MA(20): 4.92

MA(100): 5.05     MA(250): 5.16

MACD:

MACD(12,26): -0.03     Signal(12,26,9): -0.04

%K %D:

%K(14,3): 46.16     %D(3): 57.42

RSI:

RSI(14): 47.42

52-Week:

High: 7.39  Low: 3.95  Change(%): -24.5

Average Vol(K):

3-Month: 100828  10-Days 58170

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
BCRX has closed above bottom band by 46.8%. Bollinger Bands are 20.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2018-04-10T08:19:35-04:00
BioCryst and Idera postpone shareholder meetings for merger vote until July 10

2018-04-10T07:30:00-04:00
BioCryst Pharmaceuticals and Idera Pharmaceuticals Reschedule Meetings to Vote on Proposed Merger

2018-04-02T08:00:00-04:00
BioCryst Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with Idera Pharmaceuticals

2018-03-16T08:00:00-04:00
Your Daily Pharma Scoop: Abeona Update, Alexion Data, Solid Biosciences Setback

2018-03-15T09:47:50-04:00
BioCryst launches late-stage study of BCX7353 in HAE

2018-03-02T08:00:00-05:00
Your Daily Pharma Scoop: Portola Drops On AndexXa Update, NovaVax Top-Line Results, Idera Commences Late-Stage Study With IMO-2125

2018-02-28T10:18:29-05:00
BioCryst commences long-term safety study of BCX7353 in HAE patients; shares up 2%

2018-02-27T19:38:04-05:00
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q4 2017 Results - Earnings Call Transcript

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Bio Therapeutic Drugs

Shares Out. (M)

98.66

Shares Float (M)

94.66

% Held by Insiders

4.10

% Held by Institutions

Shares Short (K)

10796

Shares Short Prior Month (K)

11090

Stock Financials

EPS

-0.780

EPS Est. Current Year

-0.750

EPS Est. Next Year

-0.780

EPS Est. Next Quarter

-0.180

Forward EPS

-0.899

Book Value (p.s.)

5.700

PEG Ratio

-0.27

Profit Margin

Operating Margin

-227.95

Return on Assets (ttm)

-49.1

Return on Equity (ttm)

-154.2

Qtrly Rev. Growth

-56.7

Gross Profit (p.s.)

0.200

Sales Per Share

EBITDA (p.s.)

-0.399

Qtrly Earnings Growth

Operating Cash Flow (M)

-41.14

Levered Free Cash Flow (M)

-12.52

atoplab.com

Valuation

P/E

-6.28

P/E Growth Ratio

P/BV

0.86

P/S

1610630016.00

P/CF

-11.75

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.